Hydroxyurea is a demonstrated antineoplastic agent, which is believed to block DNA replication by inhibiting R1 and R2 (ribonucleotide reductase) via destruction of the free radical at the enzymes active site. Induces apoptosis of in vitro myelogenous leukemia lymphocytes, and the phosphorylation of FADD and p53.
1. Anand, S., et al. 1995. Cancer Lett. 88: 101-105. PMID: 7850765
2. Davies, B.W., et al. 2009. Mol. Cell. 36: 845-860. PMID: 20005847
3. Lu, X., et al. 2010. Cancer Sci. 101: 609-615. PMID: 20028385
4. Gui, C.Y., et al. 1997. Cell Res. 7: 91-97. PMID: 9261566
5. Hendricks, S.P. and Mathews, C.K. 1998. J. Biol. Chem. 273: 29519-29523. PMID: 9792659
See how others have used Hydroxyurea. Click on the entry to view the PubMed entry .
PMID: # 16159883
Niida, H. et al. 2005. Depletion of Chk1 Leads to Premature Activation of Cdc2-cyclin B and Mitotic Catastrophe J. Biol. Chem. 280(47): 39246-39252.
PMID: # 12930944
Schultz, N. et al. 2003. Poly(ADP-ribose) polymerase (PARP-1) has a controlling role in homologous recombination Nucleic Acids Res. 31(17): 4959-4964.
PMID: # 12615712
Xue, L. et al. 2003. Wild-type p53 regulates human ribonucleotide reductase by protein-protein interaction with p53R2 as well as hRRM2 subunits. Cancer Res . 63: 980-986.
PMID: # 12670898
Wu, H. et al. 2003. Small interfering RNA-induced suppression of MDR1 (P-glycoprotein) restores sensitivity to multidrug-resistant cancer cells. Cancer Res.. 63: 1515-1519.
PMID: # 12163450
Jin, K. et al. 2002. Stem cell factor stimulates neurogenesis in vitro and in vivo. J. Clin. Invest.. 110: 311-319.
PMID: # 11571274
Burma, S. et al. 2001. ATM phosphorylates histone H2AX in response to DNA double-strand breaks J. Biol. Chem. 276: 42462-42467.
PMID: # 11103783
Zhao, H. et al. 2000. Activation of the transcription factor Oct-1 in response to DNA damage. Cancer Res.. 60: 6276-6280.
PMID: # 10077601
Martelli , F. et al. 1999. Regulation of endogenous E2F1 stability by the retinoblastoma family proteins Proc. Natl. Acad. Sci. USA. 96: 2858-2863.
PMID: # 9418901
Duli, V. et al. 1998. Nuclear Accumulation of p21Cip1 at the Onset of Mitosis: a Role at the G2/M-Phase Transition Mol. Cell. Biol. 18: 546-557.
PMID: # 8943056
Fan, H. et al. 1996. Ribonucleotide reductase R2 component is a novel malignancy determinant that cooperates with activated oncogenes to determine transformation and malignant potential. Proc. Natl. Acad. Sci. U.S.A.. 93: 14036-14040.
Santa Cruz Biotechnology, Inc. is a world leader in the development of products for the biomedical research market. Call us Toll Free at 1-800-457-3801.
Copyright © 2007-2016 Santa Cruz Biotechnology, Inc. All Rights Reserved. "Santa Cruz Biotechnology", and the Santa Cruz Biotechnology, Inc. logo, "Santa Cruz Animal Health", "San Juan Ranch", "Supplement of Champions", the San Juan Ranch logo, "Ultracruz", "Chemcruz", "Immunocruz", "Exactacruz", and "EZ Touch" are registered trademarks of Santa Cruz Biotechnology, Inc.
All trademarks are the property of their respective owners.